Ovarian cancer: Making its own rules-again

Cancer

Volumn 119, Issue 3, 2013, Pages 474-476

  Kohn, Elise C ^a   Hurteau, Jean ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PLATINUM; PROTEIN KINASE B; SELUMETINIB; VEMURAFENIB;

BRAF GENE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY; CARCINOGENESIS; CODON; COLON CANCER; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MELANOMA; METASTASIS POTENTIAL; MITOSIS INDEX; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUELLERIAN DUCT; ONCOGENE K RAS; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PERITONEAL CAVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEOMICS; RECOMBINATION REPAIR; REVIEW; SEROUS OVARIAN TUMOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; THYROID CANCER; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84872920575     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27833     Document Type: Review

References (28)

1. Shih IeM, Kurman RJ,. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164: 1511-1518.
2. Matulonis UA, Hirsch M, Palescandolo E, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011; 6: e24433.
3. Merritt MA, Cramer DW,. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark. 2010; 9: 287-305.
4. Vang R, Shih IeM, Kurman RJ,. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009; 16: 267-282.
5. Kang J, D'Andrea AD, Kozono D,. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst. 2012; 104: 670-681.
6. Mankoo PK, Shen R, Schultz N, Levine DA, Sander C,. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS One. 2011; 6: e24709.
7. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-615.
8. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006; 30: 230-236.
9. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211: 26-35.
10. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 2010; 34: 984-993.
11. Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD,. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2010; 116: 50-56.
12. Grisham RN, Iyer G, Garg K, et al. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2012; 119: 548-554.
13. Russell SE, McCluggage WG,. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol. 2004; 203: 617-619.
14. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95: 484-486.
15. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29: 218-224.
16. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM,. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008; 198: 351-356.
17. Bell DA,. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005; 18 (suppl 2): S19-S32.
18. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003; 33: 19-20.
19. Pérez-Mancera PA, Tuveson DA,. Physiological analysis of oncogenic K-ras. Methods Enzymol. 2006; 407: 676-690.
20. Sartore-Bianchi A, Bencardino K, Cassingena A, et al. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev. 2010; 36 (suppl 3): S1-S5.
21. Lièvre A, Blons H, Laurent-Puig P,. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010; 29: 3033-3043.
22. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809-819.
23. Cantwell-Dorris ER, O'Leary JJ, Sheils OM,. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10: 385-394.
24. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
25. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
26. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A,. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101: 1308-1324.
27. Liévre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66: 3992-3995.
28. Farley J, Brady W, Birrer M, et al. Gynecologic Oncology Group. A phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum [Abstract]. Int J Gynecol Can. 2011; 21: S1-S1372.